MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
14.60
+0.17
+1.18%
Pre Market: 14.41 -0.19 -1.30% 04:03 05/01 EDT
OPEN
14.36
PREV CLOSE
14.43
HIGH
14.65
LOW
14.18
VOLUME
2
TURNOVER
--
52 WEEK HIGH
20.68
52 WEEK LOW
13.40
MARKET CAP
2.44B
P/E (TTM)
10.73
1D
5D
1M
3M
1Y
5Y
1D
ACADIA Pharmaceuticals Price Target Cut to $22.00/Share From $25.00 by UBS
Dow Jones · 2d ago
ACADIA Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 2d ago
UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $22
Benzinga · 2d ago
ACADIA PHARMACEUTICALS INC <ACAD.O>: UBS CUTS TARGET PRICE TO $22 FROM $25
Reuters · 2d ago
Acadia Pharmaceuticals price target lowered to $22 from $25 at UBS
TipRanks · 2d ago
Weekly Report: what happened at ACAD last week (0421-0425)?
Weekly Report · 2d ago
Press Release: Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
Dow Jones · 04/23 21:16
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/23 11:58
More
About ACAD
More
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Recently
Symbol
Price
%Change

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.